Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wendy Stevens

Showing results (271-280 of 295) with videos related to

Pageof 30
Sort By:
The Lancet. Microbe|April 12, 2024
Xpert MTB/RIF Ultra versus mycobacterial growth indicator tube liquid culture for detection of Mycobacterium tuberculosis in symptomatic adults: a diagnostic accuracy studyYingda L Xie, Christie Eichberg, Nchimunya Hapeela, et al.
Lancet (London, England)|January 22, 2022
Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage studyNicole Wolter, Waasila Jassat, Sibongile Walaza, et al.
ACR Open Rheumatology|March 30, 2022
47XXY and 47XXX in Scleroderma and MyositisR Hal Scofield, Valerie M Lewis, Joshua Cavitt, et al.
The Lancet. Rheumatology|January 22, 2024
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trialOliver Distler, Yannick Allanore, Christopher P Denton, et al.
Rheumatology (Oxford, England)|February 27, 2026
Scleroderma clinical trials consortium classification criteria for systemic sclerosis heart involvementLaura Ross, Andrew T Burns, André La Gerche, et al.
Autoimmunity Reviews|January 14, 2020
Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosisVanessa Smith, Ariane L Herrick, Francesca Ingegnoli, et al.
Nature Communications|October 4, 2022
Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South AfricaNicole Wolter, Waasila Jassat, Sibongile Walaza, et al.
The Lancet. Haematology|May 2, 2026
Very early [<sup>18</sup>F]FDG-PET-guided targeted therapy in untreated advanced-stage classic Hodgkin lymphoma (EORTC-1537-COBRA): primary results of a single-arm, multicentre, phase 2 trialMartin Hutchings, Arjan Diepstra, Anna Sureda Balari, et al.
Annals of the Rheumatic Diseases|April 18, 2020
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trialDinesh Khanna, Yannick Allanore, Christopher P Denton, et al.
Rheumatology (Oxford, England)|March 9, 2024
Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosisDinesh Khanna, Frank Kramer, Josef Höfler, et al.
Pageof 30

Showing results (271-280 of 295) with videos related to

Sort By:
Pageof 30
The Lancet. Microbe|April 12, 2024
Xpert MTB/RIF Ultra versus mycobacterial growth indicator tube liquid culture for detection of Mycobacterium tuberculosis in symptomatic adults: a diagnostic accuracy studyYingda L Xie, Christie Eichberg, Nchimunya Hapeela, et al.
Lancet (London, England)|January 22, 2022
Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage studyNicole Wolter, Waasila Jassat, Sibongile Walaza, et al.
ACR Open Rheumatology|March 30, 2022
47XXY and 47XXX in Scleroderma and MyositisR Hal Scofield, Valerie M Lewis, Joshua Cavitt, et al.
The Lancet. Rheumatology|January 22, 2024
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trialOliver Distler, Yannick Allanore, Christopher P Denton, et al.
Rheumatology (Oxford, England)|February 27, 2026
Scleroderma clinical trials consortium classification criteria for systemic sclerosis heart involvementLaura Ross, Andrew T Burns, André La Gerche, et al.
Autoimmunity Reviews|January 14, 2020
Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosisVanessa Smith, Ariane L Herrick, Francesca Ingegnoli, et al.
Nature Communications|October 4, 2022
Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South AfricaNicole Wolter, Waasila Jassat, Sibongile Walaza, et al.
The Lancet. Haematology|May 2, 2026
Very early [<sup>18</sup>F]FDG-PET-guided targeted therapy in untreated advanced-stage classic Hodgkin lymphoma (EORTC-1537-COBRA): primary results of a single-arm, multicentre, phase 2 trialMartin Hutchings, Arjan Diepstra, Anna Sureda Balari, et al.
Annals of the Rheumatic Diseases|April 18, 2020
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trialDinesh Khanna, Yannick Allanore, Christopher P Denton, et al.
Rheumatology (Oxford, England)|March 9, 2024
Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosisDinesh Khanna, Frank Kramer, Josef Höfler, et al.
Pageof 30